Editor's choice

Roger M PinderEditor-In-Chief, Neuropsychiatric Disease and TreatmentSchizophrenia remains one of the most debilitating and intractable illnesses in psychiatry. Despite the availability of effective drug treatment since the beginning of the psychopharmacological era in the early 1960s with the intro...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Pinder RM
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://doaj.org/article/47229b9bca1e4493bf9914ef869aab3e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:47229b9bca1e4493bf9914ef869aab3e
record_format dspace
spelling oai:doaj.org-article:47229b9bca1e4493bf9914ef869aab3e2021-12-02T04:27:02ZEditor's choice1176-63281178-2021https://doaj.org/article/47229b9bca1e4493bf9914ef869aab3e2012-07-01T00:00:00Zhttp://www.dovepress.com/editors-choice-35278-a10469https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Roger M PinderEditor-In-Chief, Neuropsychiatric Disease and TreatmentSchizophrenia remains one of the most debilitating and intractable illnesses in psychiatry. Despite the availability of effective drug treatment since the beginning of the psychopharmacological era in the early 1960s with the introduction of the first antipsychotic chlorpromazine, the subsequent development of second generation or atypical antipsychotics, and the effectiveness of certain types of psychotherapy, many patients are unresponsive and remain unwell for several years or relapse after apparent response. Only clozapine has proven efficacy in treatment-resistant schizophrenia, but many patients still do not respond. Polypharmacy is common, with many physicians choosing to augment rather than switch medications. Schizophrenia may be in part a neurodevelopmental disorder and involve changes in brain structure, and credence has been given to the idea that the prodromal phase, before overt symptoms have appeared, should already have been addressed with aggressive treatment. Various aspects of schizophrenia and its treatment, as well as the associated use of antipsychotic drugs in the treatment of the manic phase of bipolar disorder and Tourette syndrome, have been covered in the pages of Neuropsychiatric Disease and Treatment during the first half of 2012.Pinder RMDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2012, Iss default, Pp 321-322 (2012)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Pinder RM
Editor's choice
description Roger M PinderEditor-In-Chief, Neuropsychiatric Disease and TreatmentSchizophrenia remains one of the most debilitating and intractable illnesses in psychiatry. Despite the availability of effective drug treatment since the beginning of the psychopharmacological era in the early 1960s with the introduction of the first antipsychotic chlorpromazine, the subsequent development of second generation or atypical antipsychotics, and the effectiveness of certain types of psychotherapy, many patients are unresponsive and remain unwell for several years or relapse after apparent response. Only clozapine has proven efficacy in treatment-resistant schizophrenia, but many patients still do not respond. Polypharmacy is common, with many physicians choosing to augment rather than switch medications. Schizophrenia may be in part a neurodevelopmental disorder and involve changes in brain structure, and credence has been given to the idea that the prodromal phase, before overt symptoms have appeared, should already have been addressed with aggressive treatment. Various aspects of schizophrenia and its treatment, as well as the associated use of antipsychotic drugs in the treatment of the manic phase of bipolar disorder and Tourette syndrome, have been covered in the pages of Neuropsychiatric Disease and Treatment during the first half of 2012.
format article
author Pinder RM
author_facet Pinder RM
author_sort Pinder RM
title Editor's choice
title_short Editor's choice
title_full Editor's choice
title_fullStr Editor's choice
title_full_unstemmed Editor's choice
title_sort editor's choice
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/47229b9bca1e4493bf9914ef869aab3e
work_keys_str_mv AT pinderrm editoramp39schoice
_version_ 1718401180947709952